John LaRocca, a director at Elite Pharmaceuticals, has disclosed ownership of 88,534 shares in the company, according to a recent SEC filing. This report, filed on November 6, 2026, emphasizes LaRocca's continued involvement with Elite Pharmaceuticals and highlights the importance of transparency in ownership.

LaRocca's ownership stake may influence shareholder dynamics and governance within the pharmaceutical preparations industry. As stakeholders increasingly demand transparency, such disclosures are crucial for maintaining trust and confidence in corporate governance.

Background

Elite Pharmaceuticals, Inc. is a company based in Northvale, New Jersey, specializing in pharmaceutical preparations. The company is listed under the Central Index Key (CIK) number 0001053369. Elite Pharmaceuticals operates within the pharmaceutical industry, which is classified under the SIC code 2834. Recent filings show that LaRocca has been actively reporting his share ownership, with his latest filing being a Form 3.

What the Filing Says

The filing indicates that LaRocca owns 88,534 shares of common stock in Elite Pharmaceuticals. It states, "sharesOwnedFollowingTransaction: 88534," confirming his direct ownership of these shares.

Impact

This disclosure may affect various stakeholders, including investors and analysts who monitor the company's governance and ownership structure. LaRocca’s ownership can impact investor sentiment and may be seen as a vote of confidence in the company's direction.

What's Next

The filing does not say what happens next.